<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218162</url>
  </required_header>
  <id_info>
    <org_study_id>ID-LAS-301</org_study_id>
    <nct_id>NCT04218162</nct_id>
  </id_info>
  <brief_title>Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Parallel Group Study to Evaluate Efficacy and Safety of Lasmiditan Compared to Placebo in the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and&#xD;
      safety of lasmiditan tablet compared to Placebo in the acute treatment of Migraine&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2020</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Headache Pain Free at 2 Hours Post Dose</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants defined as mild, moderate, or severe headache pain becoming none.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Headache Relief</measure>
    <time_frame>2 hours post dose</time_frame>
    <description>The percentage of participants with headache pain moderate or severe which became mild or none or with headache pain mild which became none.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Headache Recurrence</measure>
    <time_frame>2 Hours Post Dose Up to 48 Hours</time_frame>
    <description>The number of participants with headache recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Use of Rescue Medication</measure>
    <time_frame>From 2 Hours Post Dose Up to 24 Hours</time_frame>
    <description>The percentage of participants who used rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events</measure>
    <time_frame>From Baseline Up to End of Study</time_frame>
    <description>Safety and tolerability was assessed by the number of participants with at least 1 treatment adverse emergent event.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">294</enrollment>
  <condition>Acute Migraine</condition>
  <arm_group>
    <arm_group_label>Lasmiditan 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan 50mg</intervention_name>
    <description>Lasmiditan 50mg</description>
    <arm_group_label>Lasmiditan 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan 100mg</intervention_name>
    <description>Lasmiditan 100mg</description>
    <arm_group_label>Lasmiditan 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to give written informed consent.&#xD;
&#xD;
          -  Male or female, aged 18 years or above.&#xD;
&#xD;
          -  Participants with migraine with or without aura fulfilling the International Headache&#xD;
             Society (IHS) diagnostic criteria 1.1 and 1.2.1 (International Headache Classification&#xD;
             (ICHD-3).&#xD;
&#xD;
          -  History of disabling migraine for at least 1 year.&#xD;
&#xD;
          -  Migraine Disability Association (MIDAS) score ≥11.&#xD;
&#xD;
          -  Migraine onset before the age of 50 years.&#xD;
&#xD;
          -  History of 3 - 8 migraine attacks per month (&lt; 15 headache days per month).&#xD;
&#xD;
          -  Females of child-bearing potential must be using or willing to use a highly effective&#xD;
             form of contraception (e.g. combined oral contraceptive, intrauterine device (IUD),&#xD;
             abstinence or vasectomized partner).&#xD;
&#xD;
          -  Able and willing to complete an electronic diary to record details of the migraine&#xD;
             attack treated with study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical condition or clinical laboratory test which in the judgment of the&#xD;
             Investigator makes the participant unsuitable for the study.&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  Known hypersensitivity to lasmiditan or to any excipient of lasmiditan oral tablets,&#xD;
             or any sensitivity to lasmiditan.&#xD;
&#xD;
          -  History or evidence of hemorrhagic stroke, epilepsy or any other condition placing the&#xD;
             participant at increased risk of seizures.&#xD;
&#xD;
          -  History of recurrent dizziness and/or vertigo including benign paroxysmal positional&#xD;
             vertigo (BPPV), Meniere's disease, vestibular migraine, and other vestibular&#xD;
             disorders.&#xD;
&#xD;
          -  History of diabetes mellitus with complications (diabetic retinopathy, nephropathy or&#xD;
             neuropathy).&#xD;
&#xD;
          -  History within the previous three years or current evidence of abuse of any drug,&#xD;
             prescription or illicit, or alcohol.&#xD;
&#xD;
          -  History of orthostatic hypotension with syncope.&#xD;
&#xD;
          -  Significant renal or hepatic impairment.&#xD;
&#xD;
          -  Participant is at imminent risk of suicide (positive response to question 4 or 5) on&#xD;
             the Columbia-Suicide Severity Rating Scale (C-SSRS) or had a suicide attempt within&#xD;
             six months prior to screening.&#xD;
&#xD;
          -  Participation in any clinical trial of an experimental drug or device in the previous&#xD;
             30 days.&#xD;
&#xD;
          -  Known Hepatitis B or C or human immunodeficiency virus(HIV) infection. History, within&#xD;
             past 12 months, of chronic migraine or other forms of primary or secondary chronic&#xD;
             headache disorder (e.g. hemicranias continua, medication overuse headache) where&#xD;
             headache frequency is ≥15 headache days per month.&#xD;
&#xD;
          -  Use of more than 3 doses per month of either opiates or barbiturates.&#xD;
&#xD;
          -  Initiation of or a change in concomitant medication to reduce the frequency of&#xD;
             migraine episodes within three (3) months prior to Screening/Visit 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IlDong Pharmaceutical Co Ltd</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lasmiditan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

